Key Highlights

  • Bluglass Ltd (ASX:BLG) was trading at A$0.195, down 9.30%, during the 23 October 2026 trading session.
  • On 23 October 2026, the company reported cash and cash equivalents of A$8.66 million at 30 September 2026.
  • The company said it received a A$1.4 million Phase II contract from Uviquity and secured an A$8.0 million R&D financing facility.

Bluglass Ltd (ASX:BLG) shares were trading at A$0.195, down 9.30%, during the 23 October 2026 trading session, compared with a 0.37% decline (down 32.70 points) for the S&P/ASX 200 (XJO), which was at 8,760.50 at 1:16 pm AEDT. BluGlass is a vertically integrated developer and manufacturer of visible gallium nitride (GaN) lasers. The move came on the same day the company released its September 2026 quarter activities update and Appendix 4C quarterly Cash Flow report, which covered contract wins, a new financing Facility and board changes.

Latest Developments

Customer contracts and collaborations

In its update dated 23 October 2026, BluGlass said it received an A$1.4 million (US$1.0 million) Phase II contract in July from U.S. photonics company Uviquity under the companies' joint development agreement. According to the company, Phase II broadens the work to additional engineering, packaging, laser integration and purchases of BluGlass visible GaN lasers. The company also said that on 21 September 2026 it announced an approximately A$286,000 (US$200,000) early-stage collaboration with a global photonics leader to assess a novel GaN-based device for scientific and medical markets, with a feasibility study expected to run for three to five months.

R&D financing facility and tax incentive refund

The 23 October 2026 update said BluGlass agreed terms in September for a new A$8.0 million Research and Development financing facility with Rockford RDF Pty Ltd, replacing the A$2.27 million Radium facility and providing approximately A$5.4 million of additional funding liquidity. The facility bears interest at 16.5% per annum with a 2.5% establishment fee. The company said it received its A$6.1 million FY26 R&D Tax Incentive refund in October, with A$2.75 million applied to the scheduled Rockford Loan repayment, and that the remaining balance is to be repaid from the FY27 refund and no later than 1 March 2028.

Quarterly cash flow and board updates

BluGlass reported quarterly customer receipts of A$1.66 million and net cash used in Operating Activities of A$3.12 million. R&D expenditure excluding staff costs was A$1.62 million, and cash and cash equivalents were A$8.66 million at quarter-end. The company said it appointed Yam Rubenstein as a Non-Executive Director on 21 August 2026 and that Jim Haden became Managing Director on 13 July 2026. It said its 2026 Annual General Meeting was scheduled for 1:30 pm AEDT on 23 October 2026.

About Bluglass Ltd

BluGlass Limited describes itself as a leading supplier of GaN laser diode products to the global photonics industry, focused on industrial, defence, biomedical and scientific markets. The company said it is one of a handful of end-to-end GaN laser manufacturers globally, with operations in Australia and the US. It uses a proprietary low temperature, low hydrogen, remote plasma chemical vapour deposition (RPCVD) Manufacturing technology. According to the company, it operates a project-to-product model, using paid customer development engagements to address technical requirements and establish pathways to future product supply.

Related Sector Context

BluGlass operates in photonics and semiconductor lasers, an area of the ASX technology landscape that includes development-stage and early-commercial companies. The company said its visible GaN laser and epitaxy capabilities are directed at defence, quantum, scientific, medical and advanced photonics applications. Development programs in this field are often customer-funded or supported by government grants and incentives, as the company's own R&D Tax Incentive arrangements illustrate. The S&P/ASX 200 benchmark was down 0.37% at 1:16 pm AEDT on 23 October 2026, a smaller move than that of BluGlass in the same session.

Risks to Weigh In

  • The company reported net cash used in operating activities of A$3.12 million for the quarter.
  • The Rockford facility bears interest at 16.5% per annum and is secured by first-ranking security over the FY26 and FY27 R&D Tax Incentive refunds.
  • The company's commercialisation strategy relies on converting customer-funded development programs into future product supply, which the company describes as a pathway.
  • Quarterly customer receipts were A$1.66 million, against payments for R&D, staff and other costs set out in the Appendix 4C.
  • The early-stage photonics collaboration is an initial feasibility study.

Catalysts on Watch

  • The 2026 Annual General Meeting, scheduled for 1:30 pm AEDT on 23 October 2026, including a management update on Q1 FY27 activities.
  • Progress on Phase II work with Uviquity.
  • The outcome of the three to five month feasibility study with the global photonics leader.
  • Repayment of the remaining Rockford loan balance from the FY27 R&D Tax Incentive refund.
  • Continued development with a Tier 1 U.S. defence prime and other strategic customers.

The Story So Far

Bluglass Ltd shares traded lower during the 23 October 2026 session, on the same day the company published its September 2026 quarter update. The company reported new customer work, an expanded financing facility, receipt of its R&D Tax Incentive refund and a quarter-end cash balance of A$8.66 million, while the S&P/ASX 200 was down 0.37% at 1:16 pm AEDT.